• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Republicans are more likely than Democrats to say they have a good friend in the other party

admin - Latest News - November 14, 2025
admin
16 views 20 secs 0 Comments




Despite a polarized, partisan political environment, most voters who consider themselves a member of a party say they have a close friend on the other side of the aisle, according to the latest national NBC News poll.



Source link

TAGS:
PREVIOUS
Man dies from a meat allergy caused by a tick bite
NEXT
Ancient RNA offers a snapshot of a mammoth's life 39,000 years ago
Related Post
October 3, 2025
Oct. 3, 2025, 1:42 PM EDTBy Kaan OzcanOzempic and Wegovy are coming to a Costco near you.Novo Nordisk, the company that makes Ozempic and Wegovy, announced Friday it will be selling the prescription injectable pens at the warehouse chain’s pharmacies. A four-week supply of the weight loss drug will cost $499 out of pocket. Novo Nordisk already sells the monthly supply for $499 at its direct-to-consumer website, and it offers the same discount through CVS and Walmart.Novo Nordisk and other manufacturers of the hugely popular weight loss drugs have been competing against compounding pharmacies, some clinics and medical spas who sell cheaper versions of the branded medications.“We want to make sure we offer the real, authentic Wegovy and Ozempic where patients seek care,” David Moore, president of Novo Nordisk U.S., told NBC News. “We know that Costco is a trusted brand.” Costco members with a prescription will pay $499 for a one-month supply. Executive members and those with Costco Citibank credit cards will receive an additional 2% discount. For members who have insurance, the price will depend on their plan.The discounted prescriptions will be available at over 600 Costco pharmacies nationwide starting Friday. Recent research on the drugs has shown their potential to reduce stroke risk, treat liver disease and protect heart health. Dr. Rekha Kumar, an endocrinologist at Weill Cornell Medicine and senior medical adviser at Found Health, said the drugs have been a big breakthrough in the treatment of diabetes, but they’re still out of reach for many people who are uninsured, or whose insurance won’t cover the prescriptions. “This will definitely improve one of the issues with access, meaning that there is another place that people can get the medicine that you know isn’t their retail pharmacy, isn’t an online telehealth pharmacy, but a large store that many people in the United States go to,” she said, even if it will not “solve the issues of insurance coverage and cost.”In 2024, 13 states cover GLP-1 drugs for obesity treatment, according to KFF, a nonpartisan health policy research group. Around 1 in 8 adults say they have used a GLP-1 agonist.“Those patients that have coverage will receive the medicine on average for $25 a month,” Novo Nordisk’s Moore said. “But that doesn’t cover everyone, so we wanted to make sure there’s a self-pay option available as well.”Around 1 in 5 people with private insurance don’t have coverage for at least one brand-name GLP-1 medication prescribed for weight loss, according to GoodRX.Dr. Harlan Krumholz, cardiologist and professor of medicine at Yale School of Medicine said that he’s happy to see greater accessibility for the medications, but they won’t reach the people that need them the most if they can’t pay $499 a month.“The people who have the greatest need for these medications are precisely the people who are in lower socioeconomic strata who have either poor insurance or no insurance, and don’t have the discretionary funds to be spending on medications,” he said.“If we really want to make the biggest difference on the health of the nation, we have to make sure that the people who would benefit the most have access to medications that are being shown to be beneficial.” Kaan OzcanKaan Ozcan is an intern with NBC News’ Health and Medical Unit. 
November 5, 2025
Nov. 4, 2025, 10:15 PM EST / Updated Nov. 5, 2025, 3:40 AM ESTBy Mithil Aggarwal and Steve KopackHONG KONG — International markets plunged Wednesday as stocks across the Asia-Pacific region sold off on worries about the sky-high valuations of artificial intelligence and tech companies.The Kospi stock index in South Korea plunged more than 6% at its lowest point. Japan’s Nikkei 225 average slid about 4.5%, and Hong Kong’s Hang Seng index tumbled more than 1%. Stocks in Taiwan also fell around 2.5%.European markets also opened lower. Britain’s FTSE 100 index dropped over 0.25% and futures for Germany’s benchmark stock index showed a decline of 1.2%, while the major French index showed a drop of more than 0.5%.U.S. stock futures, an indication of where markets will open, showed that losses were likely to continue Wednesday after the opening bell rings in New York. S&P 500 futures pointed to a drop of 0.5%, and Nasdaq futures indicated a decline of about 1% on Wednesday.While Asian markets pared some of their losses from earlier in the day, the indices closed lower across the board, which economists said was an indicator of how reliant tech companies, even in Asia, are on the U.S.“There are some Asian economies — Taiwan the most, followed by South Korea — that are really dependent on U.S. tech companies,” said Alicia García-Herrero, chief economist for Asia-Pacific at Natixis in Hong Kong.“It’s about the export of chips and more generally the ecosystem,” she said. “It’s very correlated.”The selloff came after a day of significant selling in the United States that brought the recent global market rally to a halt. The S&P 500 closed Tuesday down 1.1%, the Nasdaq tumbled 2%, and the Russell 2000 fell 1.8%.The largest publicly traded company in the world, Nvidia, dropped nearly 4% on Tuesday. Palantir, another AI firm whose business involves government contracts, sank nearly 8% even after it beat Wall Street’s earnings expectations. “If you look at the graph for the whole index and how much that index has been contributed by AI stocks, you just can’t believe that’s sustainable,” García-Herrero said. Last week, the Kospi hit a record high, fueled by gains in AI stocks. Taiwan’s benchmark index, TWI, has gained 20% this year, driven in part by the 40% gain seen by TSMC, which supplies chips to Nvidia and other tech companies. But on Wednesday, the months-long rally came to a grinding halt after overvaluation warnings from Wall Street, resulting in a steep selloff, with shares of global electronics giant Samsung falling 5.5% and chipmaker SK Hynix dropping more than 6%. SoftBank, a major investor in AI firms, sank more than 14%, wiping out more than $30 billion in market value.Hot stock market fuels concerns about possible Wall Street bubble02:02Late Monday, the CEOs of Goldman Sachs and Morgan Stanley warned that a possible market pullback may be on the horizon. Matters were made worse by lackluster earnings Tuesday afternoon from Advanced Micro Devices and Super Micro Computer, both of which manufacture chips used for AI services.Enthusiasm about artificial intelligence and the companies that produce AI services has been overflowing for months. Companies from Amazon to Microsoft to OpenAI have announced a steady stream of multibillion-dollar deals with one another, raising questions over the sustainability of the industry and its sources of funding.U.S. stocks are coming off a remarkable run, repeatedly setting recent record highs. For the year so far, the S&P 500 is still up more than 15%. The Nasdaq Composite, which more closely tracks the largest tech companies, has still gained more than 20% this year.Mithil Aggarwal reported from Hong Kong, and Steve Kopack reported from New York.Mithil AggarwalMithil Aggarwal is a Hong Kong-based reporter/producer for NBC News.Steve KopackSteve Kopack is a senior reporter at NBC News covering business and the economy.Jay Ganglani contributed.
November 25, 2025
Nov. 25, 2025, 12:57 PM ESTBy Erika EdwardsLouisiana Surgeon General Ralph Abraham — a vocal supporter of the “Make America Healthy Again” movement and a harsh critic of Covid shots — has been named principal deputy director at the Centers for Disease Control and Prevention.A spokesperson for the Department of Health and Human Services confirmed the appointment to NBC News, though it hadn’t been made public as of Tuesday afternoon.The principal deputy director at the CDC is a high-level appointment. As second in command, Abraham would be in a position to act as a key adviser on a variety of public health issues.A three-term Louisiana congressman, Abraham practiced for 10 years as a veterinarian before going to medical school. According to his biography on the Louisiana Department of Health website, Abraham was a “practicing family medicine physician” when he was appointed as state surgeon general in 2024. He described himself as a “country doctor” in an essay published in April.While Abraham is licensed to practice medicine in Louisiana, the Louisiana Illustrator reported in February that he did not appear to be board-certified in the specialty of family medicine. A search for Abraham on the American Board of Family Medicine’s website yielded no results. A separate search on the Louisiana State Board of Medical Examiner’s site lists Abraham as a general practitioner but not a family medicine doctor. (Board certification isn’t required to practice any particular specialty, but it’s viewed as an extra layer to ensure a doctor’s credentials, experience and expertise, according to the American Board of Physician Specialties.) Abraham has been vocal in his opposition of Covid vaccines. In September, he told the Shreveport Times that he “sees Covid vaccine injuries every day.” There was no explanation of the kind of injuries he was referring to.In February, The Associated Press reported that Abraham directed the Louisiana Department of Health, in an internal memo, to “no longer promote mass vaccination” through media campaigns like those for flu shots typically seen at the beginning of the winter respiratory virus season. The AP obtained the memo signed by Abraham. Abraham’s office did not immediately respond to a request for comment. While flu activity is low so far this season, according to the CDC’s latest flu report, Louisiana is reporting the highest levels of flu-like illnesses in the country.In the past year, with Abraham at the helm, the state’s Department of Health waited several months after two babies died of whooping cough before formally alerting the public about a rise in cases across the state.On X, Abraham touted a drug called leucovorin as a promising treatment for some children with autism. There is limited evidence that it could help a small number of children, but large studies suggesting broad benefits are lacking.As a Republican candidate for governor for Louisiana in 2019, Abraham released TV ads taking aim at abortion rights and the transgender community.Erika EdwardsErika Edwards is a health and medical news writer and reporter for NBC News and “TODAY.”Pilar Melendez contributed.
November 9, 2025
Brain cooked by TikTok? Try filming a video of yourself being bored
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved